Irinotecan and Anti-PD-L1 antibodies are thought to act synergistically: while Irinotecan reduces the density of regulatory T cells and increases tumor antigen presentation via major histocompatibility complex (MHC)-1, anti-PD-L1 antibodies block the likewise upregulated PD-L1 expression [67]. This evidence concerns the gene CD274 and neoplasm.